Autolus Therapeutics PLC (AUTL)
3.92
+0.05
(+1.29%)
USD |
NASDAQ |
May 24, 16:00
3.93
+0.01
(+0.26%)
After-Hours: 20:00
Autolus Therapeutics Cash from Financing (Quarterly): 561.44M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 561.44M |
| December 31, 2023 | 0.023M |
| September 30, 2023 | 0.004M |
| June 30, 2023 | -0.219M |
| March 31, 2023 | -0.691M |
| December 31, 2022 | 223.51M |
| September 30, 2022 | 0.102M |
| June 30, 2022 | 0.00 |
| March 31, 2022 | -0.001M |
| December 31, 2021 | 147.42M |
| September 30, 2021 | -0.23M |
| Date | Value |
|---|---|
| June 30, 2021 | 13.55M |
| March 31, 2021 | 123.32M |
| December 31, 2020 | 0.392M |
| September 30, 2020 | 0.01M |
| June 30, 2020 | -0.297M |
| March 31, 2020 | 74.31M |
| December 31, 2019 | 0.034M |
| September 30, 2019 | -0.576M |
| June 30, 2019 | 109.40M |
| March 31, 2019 | 0.004M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.691M
Minimum
Mar 2023
561.44M
Maximum
Mar 2024
62.58M
Average
0.0285M
Median
Cash from Financing (Quarterly) Benchmarks
| Adaptimmune Therapeutics PLC | 29.24M |
| Biodexa Pharmaceuticals Plc | -- |
| NuCana PLC | 1.758M |
| TC BioPharm (Holdings) PLC | 1.183M |
| Mereo BioPharma Group PLC | -- |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -40.51M |
| Cash from Investing (Quarterly) | -0.533M |
| Free Cash Flow | -151.58M |
| Free Cash Flow Per Share (Quarterly) | -0.1848 |
| Free Cash Flow to Equity (Quarterly) | -41.05M |
| Free Cash Flow to Firm (Quarterly) | -28.71M |
| Free Cash Flow Yield | -20.79% |